Sex‐ and Gender‐Based Reporting in Antihypertensive Medication Literature Informing Hypertension Guidelines

• DOI: 10.1161/jaha.123.030613
• Publication Date: 2024-02-29T10:17:38Z
• Authors: Nabilah Gulamhusein; Keila Turino Miranda; Sandra M. Dumanski; María Carlota Gon...; Ifeoma Ulasi; Arvind Conjeevaram; Sofia B. Ahmed
• Keywords: 03 medical and health sciences; hypertension; 0302 clinical medicine; RC666-701; gender; sex; Diseases of the circulatory (Cardiovascular) system; guidelines; adverse events; Original Research

Background Hypertension is the leading modifiable cardiovascular risk factor with recognized sex‐ and gender‐based differences. We assessed the incorporation of sex and gender reporting in the antihypertensive medication literature informing hypertension guidelines.

Methods and Results Literature cited in the International Society of Hypertension (2020), European Society of Cardiology/European Society of Hypertension (2018), American College of Cardiology/American Heart Association (2017), Latin American Society of Hypertension (2017), Pan‐African Society of Cardiology (2020), and Hypertension Canada (2020) guidelines was systematically reviewed. Observational studies, randomized controlled trials, and systematic reviews involving antihypertensive medications were included. Studies with participants of a single sex, guidelines, and commentaries were excluded. Data on study participation‐to‐prevalence ratio by sex, analysis of baseline demographics and study outcomes by sex, and stratification of adverse events by sex were extracted. Of 1659 unique citations, 331 studies met inclusion criteria. Of those, 81% reported the sex of participants, and 22% reported a male‐to‐female participation‐to‐prevalence ratio of 0.8 to 1.2. Three percent of studies stratified baseline characteristics by sex, and 20% considered sex during analysis through statistical adjustment or stratification. Although 32% of studies reported adverse events, only 0.6% stratified adverse events by sex. Most (58%) studies reporting sex/gender used sex and gender terms interchangeably.

Conclusions Incorporation of sex‐ and gender‐based considerations in study population, analysis, or reporting of results and adverse events is not common in the antihypertensive medication literature informing international hypertension guidelines. Greater attention to sex‐ and gender‐based factors in research is required to optimally inform management of hypertension.